The SHR-7782 injection of Hengrui Medicine’s subsidiary has been approved for clinical trials of the drug
August 15, 2025
Source: drugdu
54
Beijing Business Today (Reporter Wang Yinhao, Intern Reporter Song Yuying) On August 14th, Hengrui Medicine announced that its subsidiary, Suzhou Shengdiya Biomedical Co., LTD., has received the "Notice of Approval for Clinical Trials of SHR-7782 Injection" issued by the National Medical Products Administration and will commence clinical trials in the near future.
The announcement shows that SHR-7782 injection is a therapeutic biological product independently developed by the company. It can specifically bind to the surface antigens of tumor cells and kill tumor cells, and is intended for the treatment of advanced solid tumors. At present, no similar drugs have been approved for marketing either at home or abroad.
https://finance.eastmoney.com/a/202508143484248589.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Investigation raises concerns over tooth stem cell banking claims August 21, 2025
- Seniors Neglecting Steps To Protect Heart Health, Study Says August 21, 2025
- Pfizer’s $5.4 billion gamble fails August 21, 2025
- InnoCare Pharma’s new anticancer drug Mesutoclax completes first patient dosing in clinical trial August 21, 2025
- Novartis’ innovative drug Noradrena approved for IgA nephropathy in China August 21, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
